As we enter into a New Year, albeit under another UK wide lockdown, we have some taken some time to reflect on our progress over the past 12 months and identify what really matters to our growing customer base going into 2021. In doing so we realise we have much to celebrate and look forward to!
Over the past year we have taken leaps and strides forward with our peptide technology and expanded our user base to a global level, both of which are extremely exciting. Of particular note was the launch of our two new product lines; PeptiSols® and PeptiInks®. PeptiSols® allow our users to tailor the mechanical properties of their 3D PeptiGel® scaffolds which is important when identifying the effect of hydrogel mechanical strength on cell behaviour. PeptiInks® are based on our core PeptiGel® product, and are specifically formulated to enable users to bioprint a range of 3D culture systems and human tissue models, thus generating models in a reproducible way with improved physiological relevance. An example of their application can be found in a recent publication in Acta Biomaterialia where Angela Imere from Manchester University et al. bioprinted a tendon synovial sheath mimic.
We were also excited to win two Innovate UK grants in 2020. The first was a Knowledge Transfer Partnership working with Dr Armando del Rio Hernandez, Imperial College London, where we will be capitilising on our ability to tailor our peptide hydrogel properties to mimic the mechanical and chemical environment of both healthy and cancer tissue. We will explore independently the influence of each on cell activation, survival and growth and investigate mechanotransduction on signalling pathways. The second is to establish a new collaboration with biotechnology companies Qkine and Cellesce to develop fully synthetic animal-free scaffolds that overcome barriers in sustainable and scalable organoid culture.
All such activity was enabled by MBG closing an investment round with contributions received from three partners; Deepbridge Capital, KERO and greater Manchester and Cheshire Life Science Fund. This has enabled growth of our team, bringing marketing, sales and cell culture specialists on board, as well as expanding the company scientific expertise.
Moving forward we are excited to expand our activities and user base even further. The scene has been set internally as we have quadrupled the footprint of our lab and office facilities at Alderley Park, Cheshire, and externally by the launch of our new website, www.manchesterbiogel.com. Go check it out and find out more about how our peptide hydrogel products can help you save time in your research and enable to you gain reproducible, reliable and clinically translatable research data.
Finally, our new larger team is now widening the company’s remit – offering Manchester BIOGELs’ unique hydrogels to the pharmaceutical, biotechnology and drug discovery industries, in addition to academic users. Get in touch at email@example.com to find out how we can help you.